Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.25 USD | +0.57% | -14.08% | +58.13% |
05-16 | UBS Adjusts Rani Therapeutics Price Target to $8 From $4, Maintains Buy Rating | MT |
05-07 | HC Wainwright Adjusts Price Target on Rani Therapeutics Holdings to $13 From $12, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+58.13% | 138M | |
+9.58% | 115B | |
+12.41% | 107B | |
-12.38% | 22.31B | |
-3.55% | 21.6B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B | |
-24.50% | 8.28B |
- Stock Market
- Equities
- RANI Stock
- News Rani Therapeutics Holdings, Inc.
- Rani Therapeutics Reports 'Successful' Oral Delivery of Humira in High-Capacity Pill in Preclinical Study